About Mologen
MOLOGEN AG is a biopharmaceutical company located in Berlin, Germany and specializes in the development of novel DNA-based medicines against cancer and vaccines against infectious diseases.
The international patented platform technologies MIDGE® and dSLIM® are the foundation for all business activities. The current focus is the clinical development program of MGN1703, an immunomodulator and TLR9 agonist developed for patients with metastasized solid tumors.
MOLOGEN is looking for a strategic development and marketing partner for its cancer medicine MGN1703. The partner shall have strong clinical development, registration and marketing expertise in oncology or vaccine development.
The company was founded in 1998 and was one of the first biotechnology companies to go public.
MOLOGEN AG shares are listed on the Prime Standard segment of the Frankfurt Stock Exchange (ISIN DE 0006637200).
- Focus : Manufacturer
- Industry : Pharma
